Jefferies lowered the firm’s price target on Bicycle Therapeutics (BCYC) to $42 from $53 and keeps a Buy rating on the shares. For the FY24 ...

Eli Lilly (NYSE: LLY) stock defied today's market downturn, rising 2.6% through 11:15 a.m. ET on the back of two positive ...

Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara ...

A British study found that virtual chromoendoscopy has a higher neoplasia detection rate than other endoscopic modalities ...

J&J said it is seeking a preliminary injunction for Samsung Bioepis' close copy of Stelara over an unauthorized sublicense deal with a private label provider, which the drugmaker declined to identify.

"Hi, I'm Mendy Pellin and I have Ulcerative Colitis." Join Mendy Pellin and hear from a panel of experts on living with Crohn ...

Up to 40% of patients with inflammatory bowel disease (IBD) experience extraintestinal manifestations (EIMs), with the ...

Turmeric and honey contain many compounds that may help reduce inflammation, improve inflammation-related conditions, and ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...

Selarsdi is approved by the FDA in several presentations, including 45 mg/0.5 mL and 90 mg/mL in a single-dose prefilled ...

Inflammatory bowel disease (IBD) is associated with increased risks for genitourinary cancers, including prostate cancer and renal cell carcinoma (RCC), according to study results presented at the ...

Better cardiovascular safety and lower risk of all-cause mortality was observed among older adult patients with IBD who received ustekinumab vs vedolizumab.